Lerkanidypina – antagonista wapnia warty uwagi Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2023
Słowa kluczowe:
antagoniści wapnia, lerkanidypina, nadciśnienie tętnicze, leczenie
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze jest jednym z najważniejszych czynników ryzyka zwiększonej chorobowości i śmiertelności z przyczyn sercowo-naczyniowych. Jego skuteczne leczenie pozostaje ważnym wyzwaniem współczesnej medycyny. Poszukiwane są nowe strategie terapii oraz leki pozwalające zwiększyć skuteczną współpracę z chorymi. Lerkanidypina jest jednym z nowych leków o dużej skuteczności hipotensyjnej i dobrej tolerancji w długim okresie jej stosowania. W artykule omówiono najważniejsze cechy lerkanidypiny, wskazano na jej skuteczność w leczeniu chorych z nadciśnieniem tętniczym. Zaprezentowano szereg jej szczególnych cech, ze względu na które jest lekiem rekomendowanym w terapii pacjentów z towarzyszącą chorobą nerek. Wskazano również na wyróżniający się profil bezpieczeństwa terapii lerkanidypiną, dzięki któremu jest ona dobrze tolerowana i może znaleźć coraz szersze zastosowanie u pacjentów z nadciśnieniem tętniczym.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Rozentryt, P. (2023). Lerkanidypina – antagonista wapnia warty uwagi. Medycyna Faktów , 16(2(59), 183-194. https://doi.org/10.24292/01.MF.0223.09
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Godfraind T. Discovery and Development of Calcium Channel Blockers. Front Pharmacol. 2017; 8: 286.
2. Zamponi GW, Striessnig J, Koschak A et al. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015; 67(4): 821-70.
3. Tamargo J, Ruilope LM. Investigational calcium channel blockers for the treatment of hypertension. Expert Opin Investig Drugs. 2016; 25(11): 1295-309.
4. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984; 6(5): 592-9.
5. Gupta P, Patel P, Štrauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension (Dallas, Tex : 1979). 2017; 69(6): 1113-20.
6. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertension. 2019; 5(1): 1-88.
7. Tykarski A, Filipiak K, Januszewicz A et al. 2019 Guidelines for the Management of Hypertension – Part 1–7. Arterial Hypertension. 2019; 23(2): 41-87.
8. Barchielli M, Dolfini E, Farina P et al. Clinical Pharmacokinetics of Lercanidipine. J Cardiovasc Pharmacol. 1997; 29: S1-S15.
9. Cerbai E, Mugelli A. Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci. 2018; 22(12): 4025-31.
10. Hsu PF, Cheng HM, Wu CH et al. High Short-Term Blood Pressure Variability Predicts Long-Term Cardiovascular Mortality in Untreated Hypertensives But Not in Normotensives. Am J Hypertens. 2016; 29(7): 806-13.
11. Del Pinto R, Pietropaoli D, Dobre M et al. Prognostic importance of long-term SBP variability in high-risk hypertension. J Hypertens. 2020; 38(11): 2237-44.
12. Colbourne L, Harrison PJ. Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders. Mol Psychiatry. 2022; 27(9): 3904-12.
13. Grassi G, Robles NR, Seravalle G et al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. 2017; 8(4): 155-65.
14. Leonetti G, Magnani B, Pessina AC et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002; 15(11): 932-40.
15. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive Effects of Six Calcium Antagonists: Evidence from Fourier Analysis of 24-Hour Ambulatory Blood Pressure Recordings. Curr Ther Res. 2001; 62(4): 236-53.
16. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002; 11(2): 95-100.
17. Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int. 2008; 73(7): 795-6.
18. Taddei S, Virdis A, Ghiadoni L et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension (Dallas, Tex : 1979). 2003; 41(4): 950-5.
19. Menne J, Park JK, Agrawal R et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. Faseb J. 2006; 20(7): 994-6.
20. De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens. 2014; 32(3): 565-74.
21. Canavesi M, Baldini N, Leonardi A et al. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol. 2004; 44(4): 416-22.
22. Farah R, Khamisy-Farah R, Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol. 2013; 32(1): 85-93.
23. Wu JR, Liou SF, Lin SW et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res. 2009; 59(1): 48-56.
24. Notarbartolo A, Rengo F, Scafidi V et al. Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Curr Ther Res. 1999; 60(4): 228-36.
25. Rachmani R, Levi Z, Zadok BS et al. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther. 2002; 72(3): 302-7.
26. van Zwieten PA, Pfaffendorf M, Mancia G. Attempts to improve the selectivity of calcium antagonistic drugs. Blood Press Suppl. 1996; 5: 7-9.
27. Sabbatini M, Vitaioli L, Baldoni E et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2000; 294(3): 948-54.
28. Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of Calcium Antagonists on Glomerular Arterioles in Spontaneously Hypertensive Rats. Hypertension (Dallas, Tex: 1979). 2000; 35(3): 775-9.
29. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr. 2003; 37(3): 203-12.
30. Barrios V, Escobar C, Calderón A et al. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study. Br J Cardiol. 2006; 13: 434-40.
31. Barrios V, Escobar C, Navarro A et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract. 2006; 60(11): 1364-70.
32. Klag MJ, Whelton PK, Randall BL et al. Blood Pressure and End-Stage Renal Disease in Men. N Engl J Med. 1996; 334(1): 13-8.
33. Yan P, Zhu X, Li H et al. Association of High Blood Pressure with Renal Insufficiency: Role of Albuminuria, from NHANES, 1999–2006. PLOS ONE. 2012; 7(7): e37837.
34. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004; 17(5): 259-66.
35. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005; 27(1): 73-80.
36. Robles NR, Calvo C, Sobrino J et al. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Curr Med Res Opin. 2016; 32(sup2): 29-34.
37. Fici F, Ari Bakir E, Ilkay Yüce E et al. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease. High Blood Press Cardiovasc Prev. 2020; 27(1): 43-9.
38. Viazzi F, Muiesan ML, Schillaci G et al. Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis. J Hypertens. 2016; 34(9) 1689-97.
39. Makani H, Bangalore S, Romero J et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate – a meta- analysis of randomized trials. J Hypertens. 2011; 29(7): 1270-80.
40. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther. 2009; 31(8): 1652-63.
41. Borghi C, Prandin MG, Dormi A et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl. 2003; 1: 14-21.
42. Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother. 2007; 8(14): 2215-23.
2. Zamponi GW, Striessnig J, Koschak A et al. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015; 67(4): 821-70.
3. Tamargo J, Ruilope LM. Investigational calcium channel blockers for the treatment of hypertension. Expert Opin Investig Drugs. 2016; 25(11): 1295-309.
4. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984; 6(5): 592-9.
5. Gupta P, Patel P, Štrauch B et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension (Dallas, Tex : 1979). 2017; 69(6): 1113-20.
6. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertension. 2019; 5(1): 1-88.
7. Tykarski A, Filipiak K, Januszewicz A et al. 2019 Guidelines for the Management of Hypertension – Part 1–7. Arterial Hypertension. 2019; 23(2): 41-87.
8. Barchielli M, Dolfini E, Farina P et al. Clinical Pharmacokinetics of Lercanidipine. J Cardiovasc Pharmacol. 1997; 29: S1-S15.
9. Cerbai E, Mugelli A. Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci. 2018; 22(12): 4025-31.
10. Hsu PF, Cheng HM, Wu CH et al. High Short-Term Blood Pressure Variability Predicts Long-Term Cardiovascular Mortality in Untreated Hypertensives But Not in Normotensives. Am J Hypertens. 2016; 29(7): 806-13.
11. Del Pinto R, Pietropaoli D, Dobre M et al. Prognostic importance of long-term SBP variability in high-risk hypertension. J Hypertens. 2020; 38(11): 2237-44.
12. Colbourne L, Harrison PJ. Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders. Mol Psychiatry. 2022; 27(9): 3904-12.
13. Grassi G, Robles NR, Seravalle G et al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. 2017; 8(4): 155-65.
14. Leonetti G, Magnani B, Pessina AC et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002; 15(11): 932-40.
15. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive Effects of Six Calcium Antagonists: Evidence from Fourier Analysis of 24-Hour Ambulatory Blood Pressure Recordings. Curr Ther Res. 2001; 62(4): 236-53.
16. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002; 11(2): 95-100.
17. Hart P, Bakris GL. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int. 2008; 73(7): 795-6.
18. Taddei S, Virdis A, Ghiadoni L et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension (Dallas, Tex : 1979). 2003; 41(4): 950-5.
19. Menne J, Park JK, Agrawal R et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. Faseb J. 2006; 20(7): 994-6.
20. De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens. 2014; 32(3): 565-74.
21. Canavesi M, Baldini N, Leonardi A et al. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol. 2004; 44(4): 416-22.
22. Farah R, Khamisy-Farah R, Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol. 2013; 32(1): 85-93.
23. Wu JR, Liou SF, Lin SW et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res. 2009; 59(1): 48-56.
24. Notarbartolo A, Rengo F, Scafidi V et al. Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. Curr Ther Res. 1999; 60(4): 228-36.
25. Rachmani R, Levi Z, Zadok BS et al. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther. 2002; 72(3): 302-7.
26. van Zwieten PA, Pfaffendorf M, Mancia G. Attempts to improve the selectivity of calcium antagonistic drugs. Blood Press Suppl. 1996; 5: 7-9.
27. Sabbatini M, Vitaioli L, Baldoni E et al. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2000; 294(3): 948-54.
28. Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of Calcium Antagonists on Glomerular Arterioles in Spontaneously Hypertensive Rats. Hypertension (Dallas, Tex: 1979). 2000; 35(3): 775-9.
29. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr. 2003; 37(3): 203-12.
30. Barrios V, Escobar C, Calderón A et al. The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study. Br J Cardiol. 2006; 13: 434-40.
31. Barrios V, Escobar C, Navarro A et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract. 2006; 60(11): 1364-70.
32. Klag MJ, Whelton PK, Randall BL et al. Blood Pressure and End-Stage Renal Disease in Men. N Engl J Med. 1996; 334(1): 13-8.
33. Yan P, Zhu X, Li H et al. Association of High Blood Pressure with Renal Insufficiency: Role of Albuminuria, from NHANES, 1999–2006. PLOS ONE. 2012; 7(7): e37837.
34. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004; 17(5): 259-66.
35. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005; 27(1): 73-80.
36. Robles NR, Calvo C, Sobrino J et al. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Curr Med Res Opin. 2016; 32(sup2): 29-34.
37. Fici F, Ari Bakir E, Ilkay Yüce E et al. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease. High Blood Press Cardiovasc Prev. 2020; 27(1): 43-9.
38. Viazzi F, Muiesan ML, Schillaci G et al. Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis. J Hypertens. 2016; 34(9) 1689-97.
39. Makani H, Bangalore S, Romero J et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate – a meta- analysis of randomized trials. J Hypertens. 2011; 29(7): 1270-80.
40. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther. 2009; 31(8): 1652-63.
41. Borghi C, Prandin MG, Dormi A et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl. 2003; 1: 14-21.
42. Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother. 2007; 8(14): 2215-23.